[Local combination therapy of inflammatory dermatomycosis: A review of recommendations in national and international guidelines].
BACKGROUND
Dermatomycosis, caused by fungi or dermatophytes is often accompanied by considerable inflammatory changes and is, therefore, of great clinical significance. Hence, it is reasonable to eliminate both the pathogen and all signs of inflammation by applying a drug combination of antimycotic and corticosteroid.


OBJECTIVE
How do national and international guidelines support this kind of therapy? Does consensus prevail, or are there a variety of recommendations?


METHODS
The present article uses the internationally recognized scientific search method to evaluate pharmaceuticals and discusses the results of the international recommendations.


RESULTS
The use of a corticosteroid/antimycotic combination therapy for the treatment of various types of inflammatory dermatomycosis is explicitly recommended by national and international guidelines. Although two significant German guidelines for treatment of dermatomycoses do not include usage of combination preparations, in view of their current relevance, however, their adaptation to international recommendations appears to make sense.
Klinik für Dermatologie, Venerologie und Allergologie, Charité Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Deutschland, viktor.czaika@charite.de.
V A
VA
Czaika
T
T
Zuberbier
D000287:Administration, Topical; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage* / Q000592:standards*; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000592:standards*; D003880:Dermatology / Q000592:standards*; D004359:Drug Therapy, Combination / Q000379:methods / Q000592:standards; D019317:Evidence-Based Medicine; D005858:Germany; D006801:Humans; D038622:Internationality; D017410:Practice Guidelines as Topic; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D000935:Antifungal Agents